Glycomacropeptide and essential amino acids

PBAC's latest decision on Glycomacropeptide and essential amino acids: Recommended (2016). Considered for Treatment of phenylketonuria (PKU).

Eligible population

Children aged 2 years or older with phenylketonuria requiring nutritional management with glycomacropeptide-based medical foods.

Therapy area

Metabolic

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Other

Key trials

Ney 2016

Comparator

Camino Pro Restore®

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated. Product assessed on equivalent cost per gram of protein against comparator.

Similar precedents

• Glycomacropeptide formula with docosahexaenoic acid with low phenylalanine
  similarity 0.85
• Glycomacropeptide formula with amino acids and low phenylalanine
  similarity 0.84
• Glycomacropeptide formula with docosahexaenoic acid and low phenylalanine
  similarity 0.84
• Glycomacropeptide formula with amino acids, vitamins, minerals, trace elements, carbohydrate, fat and low phenylalanine
  similarity 0.82
• Glycomacropeptide and essential amino acids with vitamins and minerals
  similarity 0.81
• Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine
  similarity 0.79